Article
Use and Toxicity of Checkpoint Inhibitors for Solid Tumor Treatment in a Veteran Population
- Author:
- Sara E. Gordon, PharmD, BCOP
- William E. Bryan III, PharmD, BCPS
- Julia M. Hammond, PharmD, BCOP
Incidence of immune-related adverse events was not impacted by dosing strategy for PD-1 inhibitors but may provide cost savings.